Jounce Therapeutics Announces Major Strategic Collaboration

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Jounce Therapeutics Announces Major Strategic Collaboration with Celgene Corporation to Develop Next-generation Immuno-oncology Therapies for Patients with Cancer

Jounce to receive upfront payment of $225 million, a $36 million equity investment and up to an additional $2.3 billion in future milestone payments across all programs included in the collaboration

Celgene to receive options to jointly develop and commercialize Jounce’s lead product candidate, JTX-2011, and additional innovative immunotherapies targeting B cells, T regulatory cells and tumor-associated macrophages

CAMBRIDGE, Mass., July 19, 2016 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc., a company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers for patient enrichment, today announced a global strategic collaboration with Celgene Corporation (NASDAQ: CELG ) focused on developing and commercializing innovative immuno-oncology treatments for patients with cancer. The collaboration includes options on Jounce’s lead product candidate, JTX-2011, targeting ICOS, and up to four early-stage programs to be selected from a defined pool of B cell, T regulatory cell and tumor-associated macrophage targets emerging from the Jounce Translational Science Platform and an additional option to equally share a checkpoint immuno-oncology program. Post option exercise, Jounce will lead global development and U.S. commercialization for JTX-2011 and one additional collaboration program.

“Jounce has built a unique immuno-oncology platform and pipeline with a focus on the development of novel cancer therapies matched to patient populations most likely to respond,” said Robert Hershberg, M.D., Ph.D., chief scientific officer, Celgene. “This collaboration allows both companies to leverage broad capabilities in immuno-oncology to bring forward a new generation of product candidates for cancer patients.”

“Celgene is the ideal partner to collaborate with Jounce to bring potentially transformational treatments to patients with cancer,” said Richard Murray, Ph.D., chief executive officer, Jounce Therapeutics. “This partnership is of significant strategic value for Jounce. With Celgene as our partner, we can broaden our platform, advance our discovery programs and execute comprehensive clinical strategies, all in the context of our approach to bring the right immunotherapies to the right patient populations.”

Under the terms of the collaboration, Jounce will receive an upfront payment of $225 million and a $36 million equity investment from Celgene. Jounce will also receive regulatory, development, and net sales milestone payments and tiered royalties on ex-U.S. sales. Aggregate payments for development, regulatory and commercial milestones could potentially be $2.3 billion in total across all programs reaching commercialization.

Celgene has the option to opt-in at defined stages of development across the programs. Following any opt-in, Celgene and Jounce will share U.S. profits and losses on all programs, as follows:

  • Jounce will retain a 60 percent U.S. profit share of JTX-2011, with 40 percent allocated to Celgene;
  • Jounce will retain a 25 percent U.S. profit share on the first additional program, with 75 percent allocated to Celgene;
  • Jounce and Celgene will equally share U.S. profits on up to three additional programs;
  • After opt-in, all development costs will be shared in a manner that is commensurate with product rights; and
  • Celgene will also receive exclusive ex-U.S. commercialization rights for each of the above programs, and Jounce is eligible to receive a royalty on any resulting ex-U.S. sales. Celgene and Jounce will equally share profits globally for the checkpoint program.

About JTX-2011 Jounce's lead product candidate, JTX-2011, is a monoclonal antibody that binds to and activates ICOS, the Inducible T cell CO-Stimulator, a protein on the surface of certain T cells that is believed to stimulate an immune response against a patient’s cancer. We are developing JTX-2011 to treat solid tumors as a single agent and in combination with other therapies. JTX-2011 is expected to enter the clinic in the second half of 2016.

About the Jounce Translational Science Platform Jounce’s Translational Science Platform applies an unbiased bioinformatics-based approach to interrogate particular cell types within the human tumor microenvironment (the cellular environment that makes up a tumor). The platform is designed to prioritize targets and identify related biomarkers to match the right therapy to the right patients.

About Jounce Therapeutics Jounce Therapeutics is an immuno-oncology company dedicated to transforming the treatment of cancer. The company is discovering and developing novel cancer immunotherapies designed to harness the immune system to attack tumors and provide long-lasting benefits to patients. Jounce integrates translational science insights, including identification of related biomarkers designed to match the right immunotherapy to the right patients. The company is advancing programs that leverage contributions from its world-class founders, as well as knowledge acquired from Jounce’s Translational Science Platform, to create a sustainable “discovery to human proof-of-concept” product engine with the potential to drive significantly more durable responses to treatment. Founded by world leaders in tumor immunology, cancer biology and clinical and translational medicine, Jounce Therapeutics was launched in 2013 with funding from leading life sciences investor, Third Rock Ventures. For more information, please visit www.jouncetx.com .

Follow Jounce on social media: @JounceTx , Facebook , LinkedIn

 

Media Contact: Dan Budwick Pure Communications, Inc. (973) 271-6085 dan@purecommunicationsinc.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Innogen's Arcera Deal Tests Its GLP-1 Global Reach

Updated Category News Views 100

A License Deal With Actual Cash Attached Drug licensing announcements can smell like expensive perfume: plenty of promise, hard to tell what is really in the bottle. This one at least arrives with a concrete number. Innogen Pharmaceuticals will receive US$38 million in upfront and near-term milestone payments from Arcera Life Sciences for Efsubaglutide Alfa, including a...

Continue Reading
Markley’s Lowell Campus Turns Data Land Into Arboretum

Updated Category News Views 279

Server halls rarely get credited with restoring a landscape, which is why Markley’s Lowell campus caught my eye. On November 18, 2026, the company said its Lowell data center campus had earned Level I arboretum accreditation from the ArbNet Arboretum Accreditation Program. ArbNet describes itself as the only international accreditation program specifically for arboreta,...

Continue Reading
Chemours Legal Succession Gets a Long Transition Runway

Updated Category News Views 155

A corporate-law handoff rarely sets pulses racing, but this one deserves a proper look. Chemours is replacing its long-serving general counsel while keeping the departing executive in the building for four additional months. That is not flashy, and thank goodness for that. In a global chemicals company, legal leadership touches regulation, compliance, governance,...

Continue Reading
Sinopec's Green Fuel Push Meets a Hard Reality Check

Updated Category News Views 128

A refinery giant talking about green jet fuel at a climate summit is exactly the sort of thing that makes old energy hands squint first—and then check the asset list. Sinopec did bring more than lofty language to its Nov. 16 COP31 side event in Antalya: it brought long-range energy forecasts, named fuel-production routes, hydrogen infrastructure and operating projects....

Continue Reading
Vector Adds Mesa Division 10 Veteran for Arizona Growth

Updated Category News Views 140

A toilet-partition deal rarely raises eyebrows, but this one has the sturdy logic investors ought to notice. Vector Building Products has acquired Mesa-based Partitions & Accessories Co., a Division 10 specialist that has served Arizona contractors since 1978. It is not glamorous work. It is, however, the sort of necessary, specification-driven business that gets embedded...

Continue Reading
Mar-Jac's Safety Milestone Carries Real Operational Weight

Updated Category News Views 125

Four million worked hours without a lost-time accident is the sort of number that ought to make people pause, especially in poultry processing. Mar-Jac Poultry’s Gainesville facility earned Workplace Safety recognition from the Greater Hall Chamber of Commerce after reaching that mark, and this is one corporate achievement that deserves a little less eye-rolling than...

Continue Reading
Linq's $90M Bet on the Infrastructure Behind AI Agents

Updated Category News Views 201

Ninety million dollars just landed on the least glamorous part of the AI-agent rush: the pipes. Linq, the San Francisco private company, announced the round on November 18, 2026, led by Andreessen Horowitz, with returning backing from TQ Ventures, Mucker Capital and Abstract, plus new money from Anthos and Left Lane Capital. Ben Horowitz is joining the board. That is a...

Continue Reading
A Parish Memoir That Sends Its Proceeds Back Home

Updated Category News Views 198

Some books arrive with a thunderclap; this one shows up carrying a folding chair, a prayer book, and a memory that refuses to leave. You Give Them Something to Eat, the new memoir from Fr. Michael J Rieder, is built from more than a hundred short chapters rather than one grand, polished life story. That choice fits the material. Parish life is rarely a clean parade of...

Continue Reading
Thanksgiving AI Talk Needs Better Safety Questions

Updated Category News Views 84

Thanksgiving has somehow acquired a new household hazard: somebody casually pasting private information into a chatbot between football and dessert. SBS CyberSecurity’s point is sensible, and it lands because this is no longer a niche tech habit. Pew Research Center says 49% of U.S. adults use AI chatbots, up from roughly one-third in 2024. That kind of adoption curve...

Continue Reading
IDEMIA Lands Sweden's Critical 5G Connectivity Job

Updated Category News Views 10

A hospital monitor going dark because a device was misprovisioned is not the kind of connectivity hiccup anybody gets to shrug off. That is why IDEMIA Secure Transactions winning the Region Västra Götaland assignment deserves more attention than the usual telecom plumbing announcement. The region is building what it calls Sweden's largest private 5G network, and the job...

Continue Reading

Top 5 Most Recently Viewed Articles

Mori Building Boosts Investment in SL Green’s Premier Tower

Updated Category News Views 252

Mori Building Increases Stake in Iconic One Vanderbilt Avenue In a significant development within New York’s skyline, Mori Building Co., Ltd. has expanded its investment in One Vanderbilt Avenue, acquiring an additional 5.0% interest. This comes on the heels of their earlier investment of 11.0% in 2024, marking a strong commitment to this architectural marvel situated...

Continue Reading
Vegamour Welcomes Michelle Miller as Chief Marketing Officer

Updated Category News Views 415

Vegamour Welcomes New Chief Marketing Officer Michelle Miller Vegamour is excited to announce the appointment of Michelle Miller as its first Chief Marketing Officer. A well-regarded figure in the beauty industry, Michelle brings years of experience and a proven track record of success to the company. Experience and Achievements of Michelle Miller Before joining Vegamour,...

Continue Reading
Streamlined Financing Solutions Transform Insurance Payments

Updated Category News Views 107

Revolutionizing Insurance Payments with Innovative Solutions FIRST Insurance Funding, a division of Lake Forest Bank & Trust Company, N.A., has been at the forefront of premium financing for many years. Their recent integration with ePayPolicy is set to elevate the insurance payment process, making it more accessible and user-friendly for providers and insureds alike....

Continue Reading
Range Resources Delivers Strong Q1 Results with Growth Plans

Updated Category News Views 238

Impact of Q1 2025 Results on Range Resources Range Resources Corporation (NYSE: RRC) recently revealed its first quarter financial performance, showcasing robust operating results. The company reported cash flow from operating activities reaching $330 million, highlighting strong operational efficiency. Financial Highlights for the First Quarter Key Financial Metrics In...

Continue Reading
Investing in Tomorrow: The Untapped Potential of DexCom and Roku

Updated Category News Views 122

Investing in stocks can feel like a rollercoaster ride, especially when markets take a nosedive. Historical trends remind us that, over time, stocks often bounce back. Smart investors seize opportunities during downturns to snag quality shares at bargain prices. This principle of 'buy low' remains as relevant as ever. DexCom's Dip: Opportunity or Red Flag? DexCom’s...

Continue Reading